{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:04:23Z","timestamp":1772823863025,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022933","name":"Joanne and John Dallepezze Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022933","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.ijrobp.2023.12.018","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T16:18:38Z","timestamp":1703607518000},"page":"869-877","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-3856","authenticated-orcid":false,"given":"Andreas","family":"Rimner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphna Y.","family":"Gelblum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham J.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annemarie F.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cuaron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narek","family":"Shaverdian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Fiasconaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donata","family":"von Reibnitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"McCune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Gelb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph O.","family":"Deasy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen D.","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth K.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2023.12.018_bib0001","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0002","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.ijrobp.2016.06.035","article-title":"Efficacy and toxicity analysis of NRG Oncology\/RTOG 0813 trial of stereotactic body radiation therapy (SBRT) for centrally located non-small cell lung cancer (NSCLC)","volume":"96","author":"Bezjak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0003","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0004","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.ijrobp.2005.05.034","article-title":"Clinical outcomes of a phase I\/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame","volume":"63","author":"Nagata","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.ijrobp.2023.12.018_bib0005","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/0284186X.2018.1481292","article-title":"Stereotactic body radiation therapy (SBRT) improves local control and overall survival compared to conventionally fractionated radiation for stage I non-small cell lung cancer (NSCLC)","volume":"57","author":"von Reibnitz","year":"2018","journal-title":"Acta oncologica (Stockholm, Sweden)"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0006","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2008.11.042","article-title":"Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: Four-year results of a prospective phase II study","volume":"75","author":"Fakiris","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0007","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1378\/chest.124.5.1946","article-title":"Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer","volume":"124","author":"Timmerman","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0008","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0009","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/PPO.0b013e31820a7f80","article-title":"Stereotactic ablative radiation therapy for primary lung tumors","volume":"17","author":"Heinzerling","year":"2011","journal-title":"Cancer J"},{"issue":"3","key":"10.1016\/j.ijrobp.2023.12.018_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cllc.2015.09.006","article-title":"Recurrence patterns and second primary lung cancers after stereotactic body radiation therapy for early-stage non-small-cell lung cancer: implications for surveillance","volume":"17","author":"Spratt","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0011","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.cllc.2016.11.020","article-title":"Stereotactic body radiotherapy for large (>5 cm) non-small-cell lung cancer","volume":"18","author":"Peterson","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0012","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.30375","article-title":"Multi-institutional experience of stereotactic body radiotherapy for large (\u22655 centimeters) non-small cell lung tumors","volume":"123","author":"Verma","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0013","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2015.01.045","article-title":"Stereotactic body radiation therapy for non-small cell lung cancer tumors greater than 5 cm: Safety and efficacy","volume":"92","author":"Woody","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0014","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cllc.2016.04.007","article-title":"Stereotactic body radiotherapy for T3N0 lung cancer with chest wall invasion","volume":"17","author":"Berriochoa","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0015","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jtho.2017.02.021","article-title":"Use of stereotactic ablative radiotherapy (SABR) in non-small cell lung cancer measuring more than 5 cm","volume":"12","author":"Tekatli","year":"2017","journal-title":"J Thorac Oncol"},{"issue":"11","key":"10.1016\/j.ijrobp.2023.12.018_bib0016","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1097\/JTO.0b013e3182a47181","article-title":"Stereotactic body radiation therapy for primary lung cancers >3 centimeters","volume":"8","author":"Cuaron","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0021","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/cncr.20539","article-title":"Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study","volume":"101","author":"Onishi","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0022","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0360-3016(00)01374-2","article-title":"A new approach to dose escalation in non-small-cell lung cancer","volume":"49","author":"Mehta","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0023","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ijrobp.2010.12.039","article-title":"Stereotactic body radiotherapy for medically inoperable lung cancer: Prospective, single-center study of 108 consecutive patients","volume":"82","author":"Taremi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0024","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s10147-004-0435-z","article-title":"Stereotactic body radiation therapy for early-stage non-small-cell lung cancer: The Japanese experience","volume":"9","author":"Hiraoka","year":"2004","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0025","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ijrobp.2010.04.056","article-title":"Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: Results of a phase II trial","volume":"80","author":"Bral","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.ijrobp.2023.12.018_bib32","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ijrobp.2013.08.020","article-title":"The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer","volume":"87","author":"Allibhai","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0026","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2016.11.049","article-title":"Influence of fractionation scheme and tumor location on toxicities after stereotactic body radiation therapy for large (\u22655 cm) non-small cell lung cancer: A multi-institutional analysis","volume":"97","author":"Verma","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0027","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.6004\/jnccn.2019.0059","article-title":"NCCN guidelines insights: Non-small cell lung cancer, version 1.2020","volume":"17","author":"Ettinger","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0028","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.radonc.2008.07.013","article-title":"Dose-individualized stereotactic body radiotherapy for T1-3N0 non-small cell lung cancer: Long-term results and efficacy of adjuvant chemotherapy","volume":"88","author":"Chen","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0029","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2016.09.036","article-title":"Stereotactic body radiation therapy and the influence of chemotherapy on overall survival for large (>\/=5 centimeter) non-small cell lung cancer","volume":"97","author":"Verma","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0030","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","article-title":"Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: An open-label, randomised, phase 2 trial","volume":"402","author":"Chang","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2023.12.018_bib0031","doi-asserted-by":"crossref","first-page":"109983","DOI":"10.1016\/j.radonc.2023.109983","article-title":"Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation","volume":"190","author":"Thor","year":"2023","journal-title":"Radiother Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623082524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301623082524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T11:00:11Z","timestamp":1729162811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301623082524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0360301623082524"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.018","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2023.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}